DES-话题@MedSci

#DES#

174篇内容 | 1730人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1564549, encodeId=437e1564549e1, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, objectTitle=美国国立卫生研究院（NIH）：瑞德西韦（Remdesivir）对需吸氧的COVID-19患者最有益, objectType=article, longId=194727, objectId=5098194e27b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5098194e27b4, replyNumber=0, likeNumber=23, createdTime=2020-05-27, rootId=0, userName=fusion, userId=432c14994935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5098194e27b4, moduleTitle=美国国立卫生研究院（NIH）：瑞德西韦（Remdesivir）对需吸氧的COVID-19患者最有益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5098194e27b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1558540, encodeId=5d40155854069, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, objectTitle=美国国立卫生研究院（NIH）：瑞德西韦（Remdesivir）对需吸氧的COVID-19患者最有益, objectType=article, longId=194727, objectId=5098194e27b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5098194e27b4, replyNumber=0, likeNumber=22, createdTime=2020-05-27, rootId=0, userName=fusion, userId=432c14994935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5098194e27b4, moduleTitle=美国国立卫生研究院（NIH）：瑞德西韦（Remdesivir）对需吸氧的COVID-19患者最有益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5098194e27b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1564548, encodeId=bbf21564548b6, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, objectTitle=日本批准瑞德西韦（remdesivir）治疗重度COVID-19患者, objectType=article, longId=193808, objectId=7ade193808a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ade193808a1, replyNumber=0, likeNumber=24, createdTime=2020-05-10, rootId=0, userName=fusion, userId=432c14994935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ade193808a1, moduleTitle=日本批准瑞德西韦（remdesivir）治疗重度COVID-19患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ade193808a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1558539, encodeId=d9ec155853911, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, objectTitle=日本批准瑞德西韦（remdesivir）治疗重度COVID-19患者, objectType=article, longId=193808, objectId=7ade193808a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ade193808a1, replyNumber=0, likeNumber=25, createdTime=2020-05-10, rootId=0, userName=fusion, userId=432c14994935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ade193808a1, moduleTitle=日本批准瑞德西韦（remdesivir）治疗重度COVID-19患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ade193808a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1558538, encodeId=2d951558538be, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, objectTitle=WHO意外泄漏临床试验显示，吉利德的remdesivir未能改善重症新冠COVID-19感染患者, objectType=article, longId=192964, objectId=bc3a1929646c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc3a1929646c, replyNumber=0, likeNumber=37, createdTime=2020-04-27, rootId=0, userName=fusion, userId=432c14994935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc3a1929646c, moduleTitle=WHO意外泄漏临床试验显示，吉利德的remdesivir未能改善重症新冠COVID-19感染患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc3a1929646c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1564547, encodeId=5371156454e42, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, objectTitle=WHO意外泄漏临床试验显示，吉利德的remdesivir未能改善重症新冠COVID-19感染患者, objectType=article, longId=192964, objectId=bc3a1929646c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc3a1929646c, replyNumber=0, likeNumber=31, createdTime=2020-04-27, rootId=0, userName=fusion, userId=432c14994935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc3a1929646c, moduleTitle=WHO意外泄漏临床试验显示，吉利德的remdesivir未能改善重症新冠COVID-19感染患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc3a1929646c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1564546, encodeId=f5c51564546d2, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, objectTitle=吉利德宣布开展remdesivir治疗中重度新冠病毒COVID-19患者的两项III期试验, objectType=article, longId=191476, objectId=71041914e630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71041914e630, replyNumber=0, likeNumber=41, createdTime=2020-04-06, rootId=0, userName=fusion, userId=432c14994935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71041914e630, moduleTitle=吉利德宣布开展remdesivir治疗中重度新冠病毒COVID-19患者的两项III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71041914e630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1558537, encodeId=c0f6155853e20, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, objectTitle=吉利德宣布开展remdesivir治疗中重度新冠病毒COVID-19患者的两项III期试验, objectType=article, longId=191476, objectId=71041914e630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71041914e630, replyNumber=0, likeNumber=29, createdTime=2020-04-06, rootId=0, userName=fusion, userId=432c14994935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71041914e630, moduleTitle=吉利德宣布开展remdesivir治疗中重度新冠病毒COVID-19患者的两项III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71041914e630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1564545, encodeId=047115645458e, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, objectTitle=欧洲药品管理局（EMA）：允许“同情使用”瑞德西韦（remdesivir）治疗COVID-19, objectType=article, longId=191467, objectId=538b19146ee0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=538b19146ee0, replyNumber=0, likeNumber=24, createdTime=2020-04-06, rootId=0, userName=fusion, userId=432c14994935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=538b19146ee0, moduleTitle=欧洲药品管理局（EMA）：允许“同情使用”瑞德西韦（remdesivir）治疗COVID-19, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=538b19146ee0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1558536, encodeId=feaf155853610, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, objectTitle=欧洲药品管理局（EMA）：允许“同情使用”瑞德西韦（remdesivir）治疗COVID-19, objectType=article, longId=191467, objectId=538b19146ee0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=538b19146ee0, replyNumber=0, likeNumber=36, createdTime=2020-04-06, rootId=0, userName=fusion, userId=432c14994935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=538b19146ee0, moduleTitle=欧洲药品管理局（EMA）：允许“同情使用”瑞德西韦（remdesivir）治疗COVID-19, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=538b19146ee0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1558535, encodeId=3e0d1558535d8, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, objectTitle=Cytokinetics的快速骨骼肌肌钙蛋白激活剂Reldesemtiv获得欧洲孤儿药称号，用于治疗肌萎缩性侧索硬化症, objectType=article, longId=189514, objectId=6bd71895142a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bd71895142a, replyNumber=0, likeNumber=13, createdTime=2020-03-08, rootId=0, userName=fusion, userId=432c14994935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bd71895142a, moduleTitle=Cytokinetics的快速骨骼肌肌钙蛋白激活剂Reldesemtiv获得欧洲孤儿药称号，用于治疗肌萎缩性侧索硬化症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bd71895142a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1564544, encodeId=41fc1564544aa, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, objectTitle=Cytokinetics的快速骨骼肌肌钙蛋白激活剂Reldesemtiv获得欧洲孤儿药称号，用于治疗肌萎缩性侧索硬化症, objectType=article, longId=189514, objectId=6bd71895142a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bd71895142a, replyNumber=0, likeNumber=11, createdTime=2020-03-08, rootId=0, userName=fusion, userId=432c14994935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bd71895142a, moduleTitle=Cytokinetics的快速骨骼肌肌钙蛋白激活剂Reldesemtiv获得欧洲孤儿药称号，用于治疗肌萎缩性侧索硬化症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bd71895142a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1558534, encodeId=e0d21558534cd, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, objectTitle=美国正式开启Remdesivir治疗COVID-19的临床试验，来看研究方案, objectType=article, longId=189017, objectId=d40918901ee3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d40918901ee3, replyNumber=0, likeNumber=31, createdTime=2020-03-01, rootId=0, userName=fusion, userId=432c14994935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d40918901ee3, moduleTitle=美国正式开启Remdesivir治疗COVID-19的临床试验，来看研究方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d40918901ee3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1564543, encodeId=2835156454369, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, objectTitle=美国正式开启Remdesivir治疗COVID-19的临床试验，来看研究方案, objectType=article, longId=189017, objectId=d40918901ee3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d40918901ee3, replyNumber=0, likeNumber=0, createdTime=2020-03-01, rootId=0, userName=fusion, userId=432c14994935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d40918901ee3, moduleTitle=美国正式开启Remdesivir治疗COVID-19的临床试验，来看研究方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d40918901ee3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1564542, encodeId=19ec156454232, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, objectTitle=战疫中——单抗药和 Remdesivir 组合是救星吗？, objectType=article, longId=188491, objectId=478e18849102, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=478e18849102, replyNumber=0, likeNumber=14, createdTime=2020-02-22, rootId=0, userName=fusion, userId=432c14994935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=478e18849102, moduleTitle=战疫中——单抗药和 Remdesivir 组合是救星吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=478e18849102)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1558533, encodeId=593f15585337d, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, objectTitle=战疫中——单抗药和 Remdesivir 组合是救星吗？, objectType=article, longId=188491, objectId=478e18849102, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=478e18849102, replyNumber=0, likeNumber=13, createdTime=2020-02-22, rootId=0, userName=fusion, userId=432c14994935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=478e18849102, moduleTitle=战疫中——单抗药和 Remdesivir 组合是救星吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=478e18849102)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1564541, encodeId=e1771564541d8, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, objectTitle=战疫中 - 单抗药和 Remdesivir 组合是救星吗？, objectType=article, longId=188271, objectId=3b261882e1e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b261882e1e3, replyNumber=0, likeNumber=40, createdTime=2020-02-19, rootId=0, userName=fusion, userId=432c14994935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b261882e1e3, moduleTitle=战疫中 - 单抗药和 Remdesivir 组合是救星吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b261882e1e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1558532, encodeId=e4d415585321a, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, objectTitle=战疫中 - 单抗药和 Remdesivir 组合是救星吗？, objectType=article, longId=188271, objectId=3b261882e1e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b261882e1e3, replyNumber=0, likeNumber=29, createdTime=2020-02-19, rootId=0, userName=fusion, userId=432c14994935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b261882e1e3, moduleTitle=战疫中 - 单抗药和 Remdesivir 组合是救星吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b261882e1e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1558531, encodeId=91fa15585318e, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, objectTitle=瑞德西韦（Remdesivir）治疗新冠肺炎受试者招募广告, objectType=article, longId=187825, objectId=d64718e825fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d64718e825fb, replyNumber=0, likeNumber=37, createdTime=2020-02-12, rootId=0, userName=fusion, userId=432c14994935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d64718e825fb, moduleTitle=瑞德西韦（Remdesivir）治疗新冠肺炎受试者招募广告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d64718e825fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1564540, encodeId=1a29156454056, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, objectTitle=瑞德西韦（Remdesivir）治疗新冠肺炎受试者招募广告, objectType=article, longId=187825, objectId=d64718e825fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d64718e825fb, replyNumber=0, likeNumber=27, createdTime=2020-02-12, rootId=0, userName=fusion, userId=432c14994935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d64718e825fb, moduleTitle=瑞德西韦（Remdesivir）治疗新冠肺炎受试者招募广告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d64718e825fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

DES

2020-05-29

fusion (审核中...)

前往app查看评论内容

#DES#

美国国立卫生研究院（NIH）：瑞德西韦（Remdesivir）对需吸氧的COVID-19患者最有益

2020-05-27

fusion (审核中...)

前往app查看评论内容

#DES#

美国国立卫生研究院（NIH）：瑞德西韦（Remdesivir）对需吸氧的COVID-19患者最有益

2020-05-27

fusion (审核中...)

前往app查看评论内容

#DES#

日本批准瑞德西韦（remdesivir）治疗重度COVID-19患者

2020-05-10

fusion (审核中...)

前往app查看评论内容

#DES#

日本批准瑞德西韦（remdesivir）治疗重度COVID-19患者

2020-05-10

fusion (审核中...)

前往app查看评论内容

#DES#

WHO意外泄漏临床试验显示，吉利德的remdesivir未能改善重症新冠COVID-19感染患者

2020-04-27

fusion (审核中...)

前往app查看评论内容

#DES#

WHO意外泄漏临床试验显示，吉利德的remdesivir未能改善重症新冠COVID-19感染患者

2020-04-27

fusion (审核中...)

前往app查看评论内容

#DES#

吉利德宣布开展remdesivir治疗中重度新冠病毒COVID-19患者的两项III期试验

2020-04-06

fusion (审核中...)

前往app查看评论内容

#DES#

吉利德宣布开展remdesivir治疗中重度新冠病毒COVID-19患者的两项III期试验

2020-04-06

fusion (审核中...)

前往app查看评论内容

#DES#

欧洲药品管理局（EMA）：允许“同情使用”瑞德西韦（remdesivir）治疗COVID-19

2020-04-06

fusion (审核中...)

前往app查看评论内容

#DES#

欧洲药品管理局（EMA）：允许“同情使用”瑞德西韦（remdesivir）治疗COVID-19

2020-04-06

fusion (审核中...)

前往app查看评论内容

#DES#

Cytokinetics的快速骨骼肌肌钙蛋白激活剂Reldesemtiv获得欧洲孤儿药称号，用于治疗肌萎缩性侧索硬化症

2020-03-08

fusion (审核中...)

前往app查看评论内容

#DES#

Cytokinetics的快速骨骼肌肌钙蛋白激活剂Reldesemtiv获得欧洲孤儿药称号，用于治疗肌萎缩性侧索硬化症

2020-03-08

fusion (审核中...)

前往app查看评论内容

#DES#

美国正式开启Remdesivir治疗COVID-19的临床试验，来看研究方案

2020-03-01

fusion (审核中...)

前往app查看评论内容

#DES#

美国正式开启Remdesivir治疗COVID-19的临床试验，来看研究方案

2020-03-01

fusion (审核中...)

前往app查看评论内容

#DES#

战疫中——单抗药和 Remdesivir 组合是救星吗？

2020-02-22

fusion (审核中...)

前往app查看评论内容

#DES#

战疫中——单抗药和 Remdesivir 组合是救星吗？

2020-02-22

fusion (审核中...)

前往app查看评论内容

#DES#

战疫中 - 单抗药和 Remdesivir 组合是救星吗？

2020-02-19

fusion (审核中...)

前往app查看评论内容

#DES#

战疫中 - 单抗药和 Remdesivir 组合是救星吗？

2020-02-19

fusion (审核中...)

前往app查看评论内容

#DES#

瑞德西韦（Remdesivir）治疗新冠肺炎受试者招募广告

2020-02-12

fusion (审核中...)

前往app查看评论内容

#DES#

瑞德西韦（Remdesivir）治疗新冠肺炎受试者招募广告

2020-02-12

科室
- - 订阅+
  - 更多科室
工具
服务